We are live on !
Find out more
PAP
Persistent Asset Partners Portfolio holdings
AUM
$335M
Turnover
79.96%
1-Year Est. Return
275.57%
This Fund
S&P 500
This Quarter Est. Return
+61.37%
1 Year Est. Return
+275.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$335M
AUM Growth
+$66.9M
(+25%)
Cap. Flow
-$37.3M
Cap. Flow % of AUM
Cap. Flow %
-11.13%
Top 10 Holdings %
Top 10 Hldgs %
34.76%
Holding
938
New
616
Increased
74
Reduced
90
Closed
134
Avg Time Held
Equity + Options
0.1
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.1
years
Avg Time Held Equity only
0.1
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Robinhood
HOOD
|
+$16M |
| 2 |
STMicroelectronics
STM
|
+$13.6M |
| 3 |
Amphenol
APH
|
+$10.9M |
| 4 |
Seagate
STX
|
+$7.07M |
| 5 |
Ford
F
|
+$6.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sandisk
SNDK
|
+$18.4M |
| 2 |
Lumentum
LITE
|
+$14.5M |
| 3 |
AXT Inc
AXTI
|
+$13.3M |
| 4 |
Tower Semiconductor
TSEM
|
+$11.9M |
| 5 |
Micron Technology
MU
|
+$10.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 38.35% |
| 2 | Healthcare | 29.66% |
| 3 | Financials | 6.33% |
| 4 | Miscellaneous | 6.14% |
| 5 | Consumer Discretionary | 5.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
ProQR Therapeutics
PRQR
$185M
| $440K | 0.13% |
236,454
+190,387
| +413% | +$313K |
2025 Q1
5 quarters
|
|
127
Edwards Lifesciences
EW
$50.3B
| $438K | 0.13% |
4,846
-2,069
| -30% | -$173K |
2025 Q4
2 quarters
|
|
128
Lantheus
LNTH
$6.52B
| $433K | 0.13% |
3,903
+1,261
| +48% | +$117K |
2026 Q1
1 quarter
|
|
129
Abbott
ABT
$180B
| $433K | 0.13% |
4,770
-2,009
| -30% | -$183K |
2026 Q1
1 quarter
|
|
130
CALL
Biohaven
BHVN
$1.71B
| $424K | 0.13% |
806
| – | – |
2025 Q4
2 quarters
|
|
131
Unicycive Therapeutics
UNCY
$97.8M
| $423K | 0.13% |
90,165
+63,338
| +236% | +$467K |
2026 Q1
1 quarter
|
|
132
Spruce Biosciences
SPRB
$116M
| $415K | 0.12% |
7,677
+5,149
| +204% | +$288K |
2026 Q1
1 quarter
|
|
133
Anteris Technologies
AVR
$602M
| $413K | 0.12% |
41,940
-43,973
| -51% | -$334K |
2025 Q1
5 quarters
|
|
134
PUT
Capricor Therapeutics
CAPR
$387M
| $405K | 0.12% |
1,356
-222
| -14% | -$6.73K |
2025 Q4
2 quarters
|
|
135
CALL
Replimune Group
REPL
$1.04B
| $397K | 0.12% |
1,774
+1,254
| +241% | +$7.67K |
2026 Q1
1 quarter
|
|
136
Broadcom
AVGO
$1.6T
| $396K | 0.12% |
+1,048
| New | +$420K |
2026 Q2
0 quarters
|
|
137
Ardelyx
ARDX
$798M
| $395K | 0.12% |
+77,371
| New | +$472K |
2026 Q2
0 quarters
|
|
138
uniQure
QURE
$1.54B
| $394K | 0.12% |
8,545
+658
| +8% | +$17.2K |
2025 Q4
2 quarters
|
|
139
Alcoa
AA
$11B
| $391K | 0.12% |
+7,507
| New | +$503K |
2026 Q2
0 quarters
|
|
140
Roivant Sciences
ROIV
$25.1B
| $390K | 0.12% |
+11,020
| New | +$326K |
2026 Q2
0 quarters
|
|
141
Cue Biopharma
CUE
$117M
| $389K | 0.12% |
12,332
+11,220
| +1,009% | +$254K |
2026 Q1
1 quarter
|
|
142
Mineralys Therapeutics
MLYS
$1.85B
| $389K | 0.12% |
14,410
-991
| -6% | -$27.2K |
2025 Q4
2 quarters
|
|
143
DELISTED
Forte Biosciences
FBRX
| $388K | 0.12% |
18,263
+11,519
| +171% | +$273K |
2025 Q4
2 quarters
|
|
144
Axsome Therapeutics
AXSM
$8.16B
| $385K | 0.11% |
+1,573
| New | +$341K |
2026 Q2
0 quarters
|
|
145
Erasca
ERAS
$4.76B
| $377K | 0.11% |
20,573
-7,697
| -27% | -$110K |
2026 Q1
1 quarter
|
|
146
Prothena Corp
PRTA
$435M
| $373K | 0.11% |
+38,100
| New | +$376K |
2026 Q2
0 quarters
|
|
147
Telephone and Data Systems
TDS
$3.83B
| $368K | 0.11% |
+9,948
| New | +$419K |
2026 Q2
0 quarters
|
|
148
Voyager Therapeutics
VYGR
$126M
| $366K | 0.11% |
104,543
-2,551
| -2% | -$9.7K |
2026 Q1
1 quarter
|
|
149
Cencora
COR
$64.9B
| $357K | 0.11% |
1,260
+44
| +4% | +$12.7K |
2025 Q4
2 quarters
|
|
150
Oculis Holding
OCS
$451M
| $355K | 0.11% |
+25,604
| New | +$581K |
2026 Q2
0 quarters
|
|
Similar funds
JWM
PI
TFA
SIM
OWM
SS
BIA
TODC
Persistent Asset Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Persistent Asset Partners held 938 positions worth $335M, up 25% from $268M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Persistent Asset Partners withdrew a net $37.3M in Q2 2026, closing 134 positions and reducing 90 holdings. Its most notable exit was Lumentum, an estimated $14.5M position sold in full.
By sector, the portfolio is most concentrated in Technology at 38% of assets, down from 45% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Persistent Asset Partners opened a new position in Robinhood worth $19.2M.
- Persistent Asset Partners's largest Q2 2026 buy was Robinhood: 191,095 shares worth $19.2M.
- Persistent Asset Partners added most to United Therapeutics in Q2 2026, an estimated $3.99M increase.
- Persistent Asset Partners's biggest Q2 2026 reduction was Sandisk, cutting an estimated $18.4M.
- Persistent Asset Partners fully exited Lumentum in Q2 2026, selling an estimated $14.5M.
- Persistent Asset Partners's ten largest holdings make up 35% of its $335M portfolio in Q2 2026.
- Persistent Asset Partners opened 616 new positions and closed 134 in Q2 2026.
- Persistent Asset Partners's portfolio value rose 25% quarter-over-quarter to $335M.
Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.